HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT04100096

Brexpiprazole for Borderline Personality Disorder

This study is completed in the United States, in Spain, and in Ukraine. It is testing brexpiprazole for Borderline Personality Disorder.

Personality disorders, Borderline personalityDrugFrom 18 Years to 65 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore recruiting studies on this topic

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether Brexpiprazole may be useful for adults experiencing personality disorders.

What would participation involve?

Participants may receive Brexpiprazole, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Spain, in Ukraine, and in the United States.

Who is it mainly for?

This study appears to be mainly for adults with personality disorders.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)

  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: October 17, 2019
Recruitment status
Completed
Enrollment listed in the registry
332
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug, OTHER
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Spain, Ukraine
Age range
From 18 Years to 65 Years
Official registry ID
NCT04100096
Official title
A Multicenter, Randomized, Flexible-dose, Double-blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT04100096. We help you review the study, but cannot decide medical eligibility.

Recruitment & locations

Completed

Bentonville, United States · Bellflower, United States · Beverly Hills, United States

65 more locations
  • Lancaster, United States
  • Los Angeles, United States
  • Oceanside, United States
  • San Diego, United States
  • San Rafael, United States
  • Santa Ana, United States
  • Temecula, United States
  • Upland, United States
  • Denver, United States
  • Farmington, United States
  • Hartford, United States
  • Norwich, United States
  • Boca Raton, United States
  • Coral Springs, United States
  • Fort Myers, United States
  • Gainesville, United States
  • Hialeah, United States
  • Jacksonville, United States
  • Lauderhill, United States
  • Orlando, United States
  • Alpharetta, United States
  • Decatur, United States
  • Chicago, United States
  • Naperville, United States
  • Winfield, United States
  • Kansas City, United States
  • Belmont, United States
  • Boston, United States
  • Watertown, United States
  • Rochester Hills, United States
  • Bridgeton, United States
  • O'Fallon, United States
  • Saint Charles, United States
  • St Louis, United States
  • Berlin, United States
  • Cherry Hill, United States
  • Brooklyn, United States
  • Mount Kisco, United States
  • New York, United States
  • Rochester, United States
  • Charlotte, United States
  • Raleigh, United States
  • Avon Lake, United States
  • Mason, United States
  • Middleburg Heights, United States
  • Oklahoma City, United States
  • Charleston, United States
  • Dallas, United States
  • Houston, United States
  • Richardson, United States
  • San Antonio, United States
  • Wichita Falls, United States
  • Salt Lake City, United States
  • Springville, United States
  • Woodstock, United States
  • Everett, United States
  • Sabadell, Spain
  • Barcelona, Spain
  • Madrid, Spain
  • Zamora, Spain
  • Kharkiv, Ukraine
  • Kyiv, Ukraine
  • Odesa, Ukraine
  • Poltava, Ukraine
  • Vinnytsia, Ukraine
Checked Official study record (opens in a new tab)
Registry details
Registry conditions (original wording)

Borderline Personality Disorder

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as completed.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.

Drug study icon
CompletedNCT02507206

A D1 Agonist For Working Memory

This study is completed. It focuses on personality disorders and currently lists study information in the United States.

Drug study icon
CompletedEUCTR 2020-003469-20

A double blind, randomized, placebo-controlled, adaptive 14-week Phase IIb trial to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population (PORTICO)

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.